Senior Director, Portfolio Integration Lead

Business Introduction

At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting‑edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success.

We’re uniting science, technology and talent to get ahead of disease together.

Cancer is unrelenting, but so are we. At GSK, we are committed to transforming outcomes for people with cancer through innovative science, bold ambition, and strong partnerships across the healthcare ecosystem. We focus our science where it can matter most - advancing care in cancers with high unmet need, grounded in a deep understanding of disease biology and deliberate scientific choices that connect discovery to meaningful impact in the real world.

• Provide senior scientific partnership to CDLs, particularly in areas such as disease biology, biomarker strategy, and novel treatment combinations development.
• Ensure consistent cross-programme ways of working to improve development efficiency and execution.
• Drive cross-programme portfolio working groups and ensure business level alignment.
• Drive and support clinical trial innovation based on evolving oncology treatment landscape, government regulations, basic/translational science, and emerging technologies such as AI-enabled tools.
• Strengthen the scientific and strategic positioning of a pan-asset portfolio across multiple clinical and pre-clinical assets.
• Drive initiatives that advance data and technology strategies supporting development decision-making.
• Shape engagement with external experts and governance bodies including advisory boards where relevant.

• Shape the advancement of multiple development programs within the oncology portfolio by providing scientific insights across assets, ensuring that agreed disease strategy is implemented consistently across programs.
• Prepare detailed strategic analyses and portfolio recommendations on behalf of the Disease Area Vice President, enabling effective decision-making at senior leadership and governance levels.
• Ensure alignment and coordination across Clinical Matrix Teams (CMTs) and relevant cross-functional stakeholders in Research & Development (R&D), Global Medical Affairs (GMA) and Global Product Strategy (GPS).
• Drive disease-level strategic discussions and portfolio planning, bringing a pan-asset perspective to governance discussions and portfolio prioritization.
• Serve as a subject matter expert supporting global health authority interactions, regulatory submissions and key development milestones across multiple assets.

• Serve as a scientific thought partner to CDLs across multiple asset programs, shaping key aspects of clinical development strategy for a given tumour type, including:
• disease biology and translational science
• biomarker and precision medicine approaches
• combination strategies
• emerging clinical development opportunities

• Establish and champion consistent ways of working across programs to improve efficiency and development quality.
• Drive innovation in clinical development approaches for a given disease area, including trial design, novel endpoints, and emerging technologies such as AI-enabled analytics where appropriate.

• Maintain a deep understanding of the evolving tumour disease landscape, standards of care, and emerging science.
• Shape engagement with external experts through advisory boards.
• Synthesise portfolio-level external insights to inform and strengthen development strategy across multiple programs.

• Drive initiatives that strengthen the application of data,…